- Home
- MNY vs MRSN Comparison
MNY vs MRSN Comparison
Compare MNY & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNY | MRSN |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 138.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | MNY | MRSN |
|---|---|---|
| Price | $1.28 | $27.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $30.38 |
| AVG Volume (30 Days) | 88.7K | ★ 237.3K |
| Earning Date | 12-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,182,746.00 | $33,180,000.00 |
| Revenue This Year | $11.26 | N/A |
| Revenue Next Year | $20.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $5.21 |
| 52 Week High | $2.40 | $70.73 |
Technical Indicators
Market Signals| Indicator | MNY | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 83.68 |
| Support Level | $1.28 | $27.31 |
| Resistance Level | $1.60 | $28.36 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | 0.01 | -0.26 |
| Stochastic Oscillator | 13.51 | 51.65 |
Price Performance
Historical ComparisonAbout MNY MoneyHero Limited
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.